Nostrum Laboratories Revenue and Competitors
Estimated Revenue & Valuation
- Nostrum Laboratories's estimated annual revenue is currently $24.7M per year.
- Nostrum Laboratories's estimated revenue per employee is $201,000
Employee Data
- Nostrum Laboratories has 123 Employees.
- Nostrum Laboratories grew their employee count by 2% last year.
Nostrum Laboratories's People
Name | Title | Email/Phone |
---|---|---|
1 | VP | Reveal Email/Phone |
2 | Assistant Warehouse Manager | Reveal Email/Phone |
Nostrum Laboratories Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $53.7M | 267 | 16% | N/A | N/A |
#2 | $53.1M | 264 | 21% | N/A | N/A |
#3 | $69.1M | 344 | 26% | N/A | N/A |
#4 | $22.1M | 110 | -10% | N/A | N/A |
#5 | $151.8M | 755 | 11% | N/A | N/A |
#6 | $63.9M | 318 | 13% | N/A | N/A |
#7 | $29.9M | 149 | 13% | N/A | N/A |
#8 | $1.7M | 17 | -6% | $114.3M | N/A |
#9 | $6.8M | 34 | -6% | N/A | N/A |
#10 | $12.5M | 62 | -9% | N/A | N/A |
What Is Nostrum Laboratories?
www.nostrumlabs.com
keywords:N/AN/A
Total Funding
123
Number of Employees
$24.7M
Revenue (est)
2%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Nostrum Laboratories News
2022-04-17 - Global Dermatitis Herpetiformis Drugs Market 2022 Industry ...
... Acros Organics; 3B Scientific; Allergan; Valeant Canada LP; GlaxoSmithKline Pharmaceuticals Ltd. Nostrum Laboratories, Inc.
2022-04-06 - Acetazolamide Market Size estimated to exhibit at a 4.8 ...
... Accord Healthcare Ltd. (Intas Pharmaceuticals Limited), Heritage Pharmaceuticals Inc., Nostrum Laboratories Inc., Novast Laboratories...
2022-03-22 - Pfizer yanks blood pressure meds amidst ongoing, industry ...
To start the year, Viona Pharmaceuticals recalled 33 lots of metformin hydrochloride ... A year earlier, Nostrum Laboratories twice voluntarily recalled its...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $17.8M | 123 | -20% | N/A |
#2 | $18.5M | 123 | 6% | N/A |
#3 | $20.3M | 123 | 13% | N/A |
#4 | $18.5M | 123 | -3% | N/A |
#5 | $16M | 123 | 1% | N/A |